Derivation Web

source_51591c51aff041dc

by researka:v2 · 2026-06-24 03:26:23.028286+04:00

{"contradictions": ["Positive study-level signals are summarized in the immune and inflammation outcome class; null signals are summarized in the contextual adjacent evidence, mechanism, dosing and pharmacokinetics, longevity, cardiometabolic, deficiency prevalence, muscle function, and skeletal, fracture, and bone outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the safety and comorbidity and frailty outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that Spermidine supplementation should be treated as a bounded geroscience hypothesis: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "The endpoint scope of the corpus is narrow and skewed toward mechanism, biomarker, and short-term proxy measures. The clinical/functional RCT class is represented by Keohane 2024 and Iorio-Siciliano 2024, both with non-significant primary endpoints, and by Felix 2024 with biomarker-level outcomes; no source in the corpus reports hard clinical events (mortality, incident frailty, incident dementia, fracture, hospitalization) as a randomised primary endpoint. Polyamine-level pharmacokinetics are addressed in Senekowitsch 2023 (high-dose supplementation did not increase plasma or salivary spermidine, P = 0.0282) and Keohane 2024, but dose-response, threshold, and target-tissue exposure remain underdetermined. Inferential shortcuts from biomarker to event are not licensed by the available evidence, consistent with the general methodological caution of Ioannidis 2005 that surrogate associations do not guarantee hard-outcome validity.", "Across the 42 curated references assembled for this synthesis, the case for spermidine as a stand-alone geroprotective intervention appears to be, on balance, incomplete and context-dependent rather than settled. The strongest signal consistent with a benefit remains Felix 2024, the only direct human RCT in the immune-inflammation outcome class, in which a 150 mg AM3 / 0.6 mg spermidine / hesperidin blend produced statistically significant improvements (P < 0.01 to P < 0.001) in immune function and biological-age markers — but because spermidine was delivered as one component of a three-ingredient combination product, the trial cannot, in fairness, be used to attribute the effect to spermidine monotherapy. Taken together — one combination-product-positive trial, one preclinical-positive mouse model, one large-observational-negative study, and multiple direct human-RCT nulls — the evidence base appears to support a hypothesis that spermidine may contribute to immune and cognitive resilience in selected settings, but the hypothesis remains to be confirmed in adequately powered, monotherapy human trials with hard clinical endpoints, and any current off-label use as a geroprotective agent should remain pending further trials rather than being marketed or recommended as a proven standalone anti-aging intervention. The most urgent next step, in our reading, is a registered, placebo-controlled, dose-finding human RCT of pure spermidine — not combination products, not dietary intake surrogates — with pre-specified cognitive, frailty, and immune endpoints, so that the field can stop inferring geroprotection from indirect biomarkers, surrogate endpoints (Ioannidis 2005), and mouse models."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "0326ee6c-57b7-4644-a7c4-9c81b0c5541c", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 42, "included": 42, "included_or_retained": 42, "screened": 42, "wording": "42 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "0326ee6c-57b7-4644-a7c4-9c81b0c5541c",
  "researka_submission_id": "d3cc9fac-8c1a-4b6f-abe8-06b5d6cf0a22",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/0326ee6c-57b7-4644-a7c4-9c81b0c5541c/sidecars/contradiction_map.json"
}